Related Experiment Video
Updated: Aug 11, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Mean glucose level is not an independent risk factor for mortality in mixed ICU patients
Jack J M Ligtenberg1, Sofie Meijering, Ymkje Stienstra
1University Medical Centre Groningen, Intensive and Respiratory Care Unit (ICB), 30.001, 9700 RB, Groningen, The Netherlands. j.j.m.ligtenberg@int.umcg.nl
Objective:
To find out if there is an association between hyperglycaemia and mortality in mixed ICU patients.
Design And Setting:
Retrospective cohort study over a 2-year period at the medical ICU of a university hospital.
Measurements:
Admission glucose, maximum and mean glucose, length of stay, mortality, insulin therapy and Apache-II score.
Results:
In 1085 consecutive patients, ICU- and hospital mortality were 20 and 25%, respectively. The total number of blood glucose measurements was 10.012. Admission glucose was 7.9 +/- 4.5 mmol/l (mean +/- SD), mean glucose 7.5 +/- 2.9 and maximum glucose 10.0 +/- 5.4 mmol/l. Median ICU length of stay (LOS) was 3.0 days (range 2.0-6.0 days, IQR), and hospital LOS was 16 days (range 7-32 days). In 28% of patients insulin treatment was started. Median Apache-II score was 13. 68% of patients were mechanically ventilated. Univariate analysis showed an association with ICU mortality for mean glucose (non-survivors 8.6 +/- 4.3 vs 7.2 +/- 2.4 survivors), maximum glucose (11.7 +/- 5.9 vs 9.6 +/- 5.2, non-survivors vs survivors, respectively), use of insulin (mortality 29 vs 17% in patients not using insulin) and age (61 vs 55.7 years). Gender and a history of diabetes mellitus were not associated with mortality. In a multivariate model, the Apache-II score was the only variable associated with mortality independent of other variables, including mean blood glucose.
Conclusion:
In this retrospective study mean glucose level was not an independent risk factor for mortality in mixed ICU patients.
Related Concept Videos
Hypoglycemia and Glucagon
Hyperglycemia
Hypoglycemia
Diabetes Mellitus: Type 2 and Gestational
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides